“People living with CF are particularly vulnerable to antimicrobial resistance. New antimicrobials that target infections caused by bugs commonly associated with lung infections in CF are urgently needed. We are delighted to announce this funding call aimed at stimulating new research and development into treatments with the potential to benefit people with CF.”
Dr Paula Sommer, Head of Research at Cystic Fibrosis Trust
